ClinicalTrials.gg
CompletedNCT05223868FRONTIER 1Updated Feb 13, 2026Results posted

A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis

A Phase 2 interventional study of JNJ-77242113 and Placebo in Plaque Psoriasis, sponsored by Janssen Research & Development, LLC. Completed at 76 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Psoriasis by Johnson & Johnson — 3 open to participants now, 12 under way, 7 of them phase 3. Psoriasis · Johnson & Johnson.

Enrollment
27th of 58
255 · median 222
Started
2022
with 4 others
Phase 2
12 of 76
none open now
Registered
61st of 76
by date

Among the 76 studies in Psoriasis by Johnson & Johnson, this one is the 27th largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2022, is one of 12 in phase 2, and was the 61st registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

3 of the 76 studies in Psoriasis by Johnson & Johnson are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Psoriasis by Johnson & Johnson, or all of them as a file.
02

Study summary

Th purpose of the study is to evaluate the dose response of JNJ-77242113 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.

Read the detailed description

The populations of people living with moderate to severe psoriasis is approximately 3.5 billion which are mostly managed with topical and conventional therapies. JNJ-77242113, investigational drug, targets the immune responses in the body and skin which impacts diseases, such as psoriasis and psoriatic arthritis (PsA) and this study evaluates JNJ-77242113 as options of advanced therapies in moderate to severe plaque psoriasis. The total duration of this study is up to 24 weeks which includes a screening period of less than or equal to (\<=) 4 weeks, a 16-week treatment period, and a 4-week safety follow-up period. Safety will be assessed by adverse events (AEs), clinical safety laboratory assessments, electrocardiograms (ECGs), vital signs and physical examinations.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has a diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 6 months prior to the first administration of study intervention
  • Participant be a candidate for phototherapy or systemic treatment for plaque psoriasis
  • Participant has a total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
  • Participant has a total Psoriasis area and severity index (PASI) >=12 at screening and baseline
  • Participant has a total Investigator global assessment (IGA) >=3 at screening and baseline

Exclusion criteria

Exclusion Criteria:

  • Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
  • Participant has current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
  • Participant have previously received any other therapeutic agent directly targeted to interleukin 23 receptor (IL-23R) (including but not limited to guselkumab, tildrakizumab, or risankizumab)
  • Participant has received any therapeutic agent directly targeted to interleukin 17 receptor (IL-17) or interleukin 12/23 receptor (IL-12/23) (including but not limited to secukinumab, ixekizumab, brodalumab, or ustekinumab) or has received anti-tumor necrosis factor [TNF]-alpha biologic therapy (including, but not limited to adalimumab) within 12 weeks or 5 half-lives, whichever is longer, of the first administration of study intervention
  • Participant has received agents that deplete B cells (including, but not limited to, rituximab, or alemtuzumab) within 26 weeks of the first administration of study intervention
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
255 participants (actual)

Study arms

  • Experimental
    Group 1: JNJ-77242113 Dose 1 Once Daily (QD) and Placebo

    Participants will receive JNJ-77242113 Dose 1 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.

    Drug: JNJ-77242113 · Drug: Placebo

  • Experimental
    Group 2: JNJ-77242113 Dose 2 QD and Placebo

    Participants will receive JNJ-77242113 Dose 2 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.

    Drug: JNJ-77242113 · Drug: Placebo

  • Experimental
    Group 3: JNJ-77242113 Dose 3 QD and Placebo

    Participants will receive JNJ-77242113 Dose 3 QD and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.

    Drug: JNJ-77242113 · Drug: Placebo

  • Experimental
    Group 4: JNJ-77242113 Dose 1 Twice Daily (BID) and Placebo

    Participants will receive JNJ-77242113 Dose 1 BID and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.

    Drug: JNJ-77242113 · Drug: Placebo

  • Experimental
    Group 5: JNJ-77242113 Dose 3 BID and Placebo

    Participants will receive JNJ-77242113 Dose 3 BID and placebo from Week 0 through Week 16. Participants will receive placebo to maintain the blinding of dose regimens.

    Drug: JNJ-77242113 · Drug: Placebo

  • Placebo comparator
    Group 6: Placebo

    Participants will receive placebo BID from Week 0 through Week 16.

    Drug: Placebo

Interventions

  • JNJ-77242113 tablet will be administered orally.

  • DrugPlacebo

    Placebo tablet will be administered orally.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 16

    Percentage of participants who achieved PASI-75 score (greater than or equal to \[\>=\] 75% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

Secondary outcomes

  1. Change From Baseline in PASI Total Score at Week 16

    Change from baseline in PASI total score at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  2. Percentage of Participants Who Achieved at Least 90% Improvement From Baseline in PASI (PASI-90) at Week 16

    Percentage of participants who achieved PASI-90 score (\>=90% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  3. Percentage of Participants Who Achieved 100% Improvement From Baseline in PASI (PASI-100) at Week 16

    Percentage of participants who achieved PASI-100 score (100% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  4. Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16

    The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 millimeters (mm); 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, greater than (\>) 1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Higher score indicated more severe disease.

    Time frame: At Week 16

  5. Percentage of Participants Who Achieved an IGA Score of Cleared (0) at Week 16

    The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

    Time frame: At Week 16

  6. Change From Baseline in Body Surface Area (BSA) at Week 16

    A BSA was commonly used measure of severity of skin disease. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). BSA was assessed using hand print method where the surface area of the participant's hand including the palm and all 5 digits was used as a guide to estimate 1% BSA. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0) and Week 16

  7. Change From Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptoms Scores at Week 16

    Change from baseline in PSSD symptoms scores at Week 16 was reported. PSSD was a patient-reported outcome (PRO) questionnaire designed to measure severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily symptom score when at least 3 items (\>=50 percentage of 5 items) on these scales are answered. The average value was converted into 0-100 scoring, such that symptom score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0) and Week 16

  8. Change From Baseline in PSSD Signs Score at Week 16

    Change from baseline in PSSD sign scores at Week 16 was reported. PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily sign score when at least 3 items (\>=50 percentage of 6 items) on these scales are answered. The average value was converted into 0-100 scoring, such that sign score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0) and Week 16

  9. Percentage of Participants Who Achieved PSSD Symptoms Score Equal to (=) 0 at Week 16 Among Participants With a Baseline Symptoms Score Greater Than or Equal to (>=) 1

    The PSSD was a PRO questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily symptom score when at least 3 items (\>=50 percentage of 5 items) on these scales are answered. The average value was converted into 0-100 scoring, such that symptom score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  10. Percentage of Participants Who Achieved PSSD Sign Score = 0 at Week 16 Among Participants With a Baseline Sign Score >=1

    The PSSD was a PRO questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily sign score when at least 3 items (\>=50 percentage of 6 items) on these scales are answered. The average value was converted into 0-100 scoring, such that sign score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0) , Week 16

  11. Percentage of Participants Who Achieved a Dermatological Life Quality Index (DLQI) of 0 or 1 at Week 16 Among Participants With Baseline DLQI Score Greater Than (>) 1

    The DLQI was a dermatology specific health-related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It was a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, could be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Each question was scored on a 4-point scale of 0 to 3 (0 = not at all, 1 = a little; 2 = a lot; or 3 = very much, where higher score indicated more impact on QoL). The total score was sum of scores from all 10 questions and it ranged from 0 (not at all) to 30 (very much), with a higher score indicating greater impact on HRQoL. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  12. Change From Baseline in Domain Scores of the Patient-Reported Outcomes Measurement Information System (PROMIS-29) at Week 16

    PROMIS-29, 29-item generic HRQoL survey, assesses each 7 PROMIS domains (depression; anxiety; physical function; pain interference; fatigue; sleep disturbance; ability to participate in social roles and activities) with 4 questions and pain intensity. Questions ranked on 5-point Likert Scale (1=never, 2=rarely, 3=sometimes, 4=often and 5=always). Pain intensity was rated on 11-point scale (0=no pain; 10=worst imaginable pain). Higher score= worst pain. Each domain included 4 items, plus a single pain intensity item totaling 29 items. Raw score of each PROMIS domain was converted into a standardized score with mean of 50; standard deviation (SD) of 10 (T-Score). Higher PROMIS T-score=more of concept being measured i.e. higher scores in anxiety, depression, fatigue, pain interference, sleep disturbance= worse symptoms, higher scores in physical function, social roles= better functioning. Baseline: closest measurement taken prior to/at the time of first study drug administration date.

    Time frame: Baseline (Week 0) and Week 16

  13. Percentage of Participants Who Achieved at Least a 5-point Improvement From Baseline in Each PROMIS-29 Domain at Week 16

    PROMIS-29, 29-item generic HRQoL survey, assesses each 7 PROMIS domains (depression; anxiety; physical function; pain interference; fatigue; sleep disturbance; ability to participate in social roles and activities) with 4 questions and pain intensity. Questions ranked on 5-point Likert Scale (1=never, 2=rarely, 3=sometimes, 4=often, 5=always). Pain intensity was rated on 11-point scale (0=no pain; 10=worst imaginable pain). Higher score=worst pain. Each domain includes 4 items, plus a single pain intensity item totaling 29 items. Raw score of each PROMIS domain was converted into a standardized score with mean of 50; SD of 10 (T-Score). Higher PROMIS T-score= more of the concept being measured i.e. higher scores in anxiety, depression, fatigue, pain interference and sleep disturbance) indicated worse symptoms, higher scores in physical function and social roles= better functioning. Baseline: closest measurement taken prior to/at the time of first study drug administration date.

    Time frame: Baseline (Week 0), Week 16

  14. Number of Participants With Treatment-emergent Adverse Event (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation where participants administered a product or medical device; the event needed not necessarily have a causal relationship with the treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or resulted in congenital anomaly/birth defect. TEAE was defined as any event that occurred at or after the initial administration of study agent.

    Time frame: From Week 0 through Week 20

07

Results

Posted Dec 30, 2025

Participant flow

Participant flow — Overall Study
MilestonePlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BID
Started434343414342
Completed363640404138
Not completed773124
Withdrew: Lost to follow-up130001
Withdrew: Withdrawal by subject623112
Withdrew: Other020011

Outcome measures

PrimaryPercentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 16

Percentage of participants who achieved PASI-75 score (greater than or equal to \[\>=\] 75% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 16
Percentage of participantsPlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BID
Percentage of Participants Who Achieved at Least 75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 169.337.258.151.265.178.6
Statistical analysis
  • Placebo vs JNJ-77242113 25 mg QD · Cochran-Mantel-Haenszel · p = =0.002 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose versus (vs) placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
SecondaryChange From Baseline in PASI Total Score at Week 16

Change from baseline in PASI total score at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Mean · Units on a scale
Change From Baseline in PASI Total Score at Week 16
Units on a scalePlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BID
Change From Baseline in PASI Total Score at Week 16-3.59 ± 9.436-12.76 ± 8.050-14.56 ± 6.528-12.73 ± 8.021-13.99 ± 8.653-17.44 ± 8.356
Statistical analysis
  • Placebo vs JNJ-77242113 25 mg QD · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
SecondaryPercentage of Participants Who Achieved at Least 90% Improvement From Baseline in PASI (PASI-90) at Week 16

Percentage of participants who achieved PASI-90 score (\>=90% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0 = none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved at Least 90% Improvement From Baseline in PASI (PASI-90) at Week 16
Percentage of participantsPlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BID
Percentage of Participants Who Achieved at Least 90% Improvement From Baseline in PASI (PASI-90) at Week 162.325.651.226.846.559.5
Statistical analysis
  • Placebo vs JNJ-77242113 25 mg QD · Cochran-Mantel-Haenszel · p = =0.002 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Cochran-Mantel-Haenszel · p = =0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
SecondaryPercentage of Participants Who Achieved 100% Improvement From Baseline in PASI (PASI-100) at Week 16

Percentage of participants who achieved PASI-100 score (100% improvement from baseline in PASI) at Week 16 was reported. The PASI was a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body was divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas was assessed and scored separately for erythema, induration, and scaling, which were each rated on a scale of 0 to 4 (0=none, 1 = slight, 2 = moderate, 3 = severe and 4 = very severe) and extent of involvement from 0 (indicated no involvement) to 6 (90% - 100% involvement). The PASI produced a numeric total score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved 100% Improvement From Baseline in PASI (PASI-100) at Week 16
Percentage of participantsPlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BID
Percentage of Participants Who Achieved 100% Improvement From Baseline in PASI (PASI-100) at Week 16011.625.69.823.340.5
Statistical analysis
  • Placebo vs JNJ-77242113 25 mg QD · Cochran-Mantel-Haenszel · p = =0.021 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Cochran-Mantel-Haenszel · p = =0.038 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
SecondaryPercentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16

The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 millimeters (mm); 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, greater than (\>) 1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Higher score indicated more severe disease.

Time frame:
At Week 16
Reported as:
Number · Percentages of participants
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16
Percentages of participantsPlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BID
Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 1611.639.558.151.262.864.3
Statistical analysis
  • Placebo vs JNJ-77242113 25 mg QD · Cochran-Mantel-Haenszel · p = =0.003 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
SecondaryPercentage of Participants Who Achieved an IGA Score of Cleared (0) at Week 16

The IGA assesses participant's plaque psoriasis. Lesions were graded for induration, erythema and scaling, each using a 5 point scale. Induration: 0 = no evidence of plaque elevation, 1 = minimal plaque elevation, = 0.25 mm; 2 = mild plaque elevation, = 0.5 mm; 3 = moderate plaque elevation, = 0.75 mm; 4 = severe plaque elevation, \>1 mm; Erythema: 0 = no evidence of erythema, hyperpigmentation may be present, 1 = faint erythema, 2 = light red coloration, 3 = moderate red coloration, 4 = bright red coloration; Scaling: 0 = no evidence of scaling, 1 = minimal; occasional fine scale over less than 5% of the lesion, 2 = mild; fine scale dominates, 3 = moderate; coarse scale predominates, 4 = severe; thick, scale predominates. Final IGA score of psoriasis was based upon the average of induration, erythema and scaling scores assessed on a 5 point scale: cleared (0), minimal (1), mild (2), moderate (3), or severe (4). A higher score indicated more severe disease.

Time frame:
At Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved an IGA Score of Cleared (0) at Week 16
Percentage of participantsPlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BID
Percentage of Participants Who Achieved an IGA Score of Cleared (0) at Week 16016.334.914.627.945.2
Statistical analysis
  • Placebo vs JNJ-77242113 25 mg QD · Cochran-Mantel-Haenszel · p = =0.006 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Cochran-Mantel-Haenszel · p = =0.009 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
SecondaryChange From Baseline in Body Surface Area (BSA) at Week 16

A BSA was commonly used measure of severity of skin disease. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). BSA was assessed using hand print method where the surface area of the participant's hand including the palm and all 5 digits was used as a guide to estimate 1% BSA. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0) and Week 16
Reported as:
Mean · Percentage of BSA
Change From Baseline in Body Surface Area (BSA) at Week 16
Percentage of BSAPlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BID
Change From Baseline in Body Surface Area (BSA) at Week 16-2.4 ± 16.51-11.9 ± 10.00-15.3 ± 11.41-13.3 ± 11.08-14.6 ± 14.03-21.0 ± 13.74
Statistical analysis
  • Placebo vs JNJ-77242113 25 mg QD · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
SecondaryChange From Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptoms Scores at Week 16

Change from baseline in PSSD symptoms scores at Week 16 was reported. PSSD was a patient-reported outcome (PRO) questionnaire designed to measure severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily symptom score when at least 3 items (\>=50 percentage of 5 items) on these scales are answered. The average value was converted into 0-100 scoring, such that symptom score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0) and Week 16
Reported as:
Mean · Units on a scale
Change From Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptoms Scores at Week 16
Units on a scalePlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BID
Change From Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptoms Scores at Week 16-0.8 ± 29.59-35.8 ± 29.22-36.7 ± 29.95-34.0 ± 29.19-29.4 ± 28.28-44.0 ± 31.22
Statistical analysis
  • Placebo vs JNJ-77242113 25 mg QD · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
SecondaryChange From Baseline in PSSD Signs Score at Week 16

Change from baseline in PSSD sign scores at Week 16 was reported. PSSD was a PRO questionnaire designed to measure severity of psoriasis symptoms and signs for assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily sign score when at least 3 items (\>=50 percentage of 6 items) on these scales are answered. The average value was converted into 0-100 scoring, such that sign score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0) and Week 16
Reported as:
Mean · Units on a scale
Change From Baseline in PSSD Signs Score at Week 16
Units on a scalePlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BID
Change From Baseline in PSSD Signs Score at Week 16-6.2 ± 22.38-38.6 ± 27.55-42.7 ± 28.70-41.8 ± 27.78-41.9 ± 28.65-51.1 ± 26.01
Statistical analysis
  • Placebo vs JNJ-77242113 25 mg QD · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
SecondaryPercentage of Participants Who Achieved PSSD Symptoms Score Equal to (=) 0 at Week 16 Among Participants With a Baseline Symptoms Score Greater Than or Equal to (>=) 1

The PSSD was a PRO questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily symptom score when at least 3 items (\>=50 percentage of 5 items) on these scales are answered. The average value was converted into 0-100 scoring, such that symptom score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved PSSD Symptoms Score Equal to (=) 0 at Week 16 Among Participants With a Baseline Symptoms Score Greater Than or Equal to (>=) 1
Percentage of participantsPlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BID
Percentage of Participants Who Achieved PSSD Symptoms Score Equal to (=) 0 at Week 16 Among Participants With a Baseline Symptoms Score Greater Than or Equal to (>=) 1016.323.817.127.926.2
Statistical analysis
  • Placebo vs JNJ-77242113 25 mg QD · Cochran-Mantel-Haenszel · p = =0.006 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Cochran-Mantel-Haenszel · p = =0.005 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
SecondaryPercentage of Participants Who Achieved PSSD Sign Score = 0 at Week 16 Among Participants With a Baseline Sign Score >=1

The PSSD was a PRO questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a self-administered PRO instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Items were averaged on the daily sign score when at least 3 items (\>=50 percentage of 6 items) on these scales are answered. The average value was converted into 0-100 scoring, such that sign score = average value\*10, where, 0= least severe and 100= most severe. Higher score indicated more severe disease. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0) , Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved PSSD Sign Score = 0 at Week 16 Among Participants With a Baseline Sign Score >=1
Percentage of participantsPlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BID
Percentage of Participants Who Achieved PSSD Sign Score = 0 at Week 16 Among Participants With a Baseline Sign Score >=102.314.09.816.314.3
Statistical analysis
  • Placebo vs JNJ-77242113 25 mg QD · Cochran-Mantel-Haenszel · p = =0.317 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Cochran-Mantel-Haenszel · p = =0.012 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Cochran-Mantel-Haenszel · p = =0.038 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Cochran-Mantel-Haenszel · p = =0.006 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Cochran-Mantel-Haenszel · p = =0.011 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
SecondaryPercentage of Participants Who Achieved a Dermatological Life Quality Index (DLQI) of 0 or 1 at Week 16 Among Participants With Baseline DLQI Score Greater Than (>) 1

The DLQI was a dermatology specific health-related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It was a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, could be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Each question was scored on a 4-point scale of 0 to 3 (0 = not at all, 1 = a little; 2 = a lot; or 3 = very much, where higher score indicated more impact on QoL). The total score was sum of scores from all 10 questions and it ranged from 0 (not at all) to 30 (very much), with a higher score indicating greater impact on HRQoL. The baseline was defined as the closest measurement taken prior to or at the time of the first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a Dermatological Life Quality Index (DLQI) of 0 or 1 at Week 16 Among Participants With Baseline DLQI Score Greater Than (>) 1
Percentage of participantsPlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BID
Percentage of Participants Who Achieved a Dermatological Life Quality Index (DLQI) of 0 or 1 at Week 16 Among Participants With Baseline DLQI Score Greater Than (>) 12.427.937.230.055.843.9
Statistical analysis
  • Placebo vs JNJ-77242113 25 mg QD · Cochran-Mantel-Haenszel · p = =0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
SecondaryChange From Baseline in Domain Scores of the Patient-Reported Outcomes Measurement Information System (PROMIS-29) at Week 16

PROMIS-29, 29-item generic HRQoL survey, assesses each 7 PROMIS domains (depression; anxiety; physical function; pain interference; fatigue; sleep disturbance; ability to participate in social roles and activities) with 4 questions and pain intensity. Questions ranked on 5-point Likert Scale (1=never, 2=rarely, 3=sometimes, 4=often and 5=always). Pain intensity was rated on 11-point scale (0=no pain; 10=worst imaginable pain). Higher score= worst pain. Each domain included 4 items, plus a single pain intensity item totaling 29 items. Raw score of each PROMIS domain was converted into a standardized score with mean of 50; standard deviation (SD) of 10 (T-Score). Higher PROMIS T-score=more of concept being measured i.e. higher scores in anxiety, depression, fatigue, pain interference, sleep disturbance= worse symptoms, higher scores in physical function, social roles= better functioning. Baseline: closest measurement taken prior to/at the time of first study drug administration date.

Time frame:
Baseline (Week 0) and Week 16
Reported as:
Mean · Units on a scale
Change From Baseline in Domain Scores of the Patient-Reported Outcomes Measurement Information System (PROMIS-29) at Week 16
Units on a scalePlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BID
Physical Function-1.04 ± 5.9292.30 ± 6.0605.81 ± 6.8964.55 ± 7.7893.10 ± 7.3255.81 ± 8.408
Anxiety-2.36 ± 7.971-3.98 ± 8.789-5.27 ± 8.026-5.27 ± 6.787-4.70 ± 8.570-8.31 ± 9.693
Depression-1.01 ± 6.238-3.09 ± 8.709-3.23 ± 6.576-1.96 ± 6.569-2.62 ± 7.465-3.67 ± 8.912
Fatigue-0.76 ± 5.469-2.44 ± 10.983-1.50 ± 7.801-3.09 ± 8.676-2.98 ± 7.818-3.75 ± 8.409
Sleep Disturbance0.14 ± 6.099-1.89 ± 5.859-3.45 ± 7.947-4.36 ± 6.041-1.04 ± 5.995-3.19 ± 5.705
Social Roles and Activities0.99 ± 8.3934.31 ± 9.0354.82 ± 8.5115.39 ± 10.9085.78 ± 7.5387.73 ± 9.607
Pain Interference0.09 ± 7.819-6.79 ± 9.038-7.41 ± 9.867-7.18 ± 7.956-3.98 ± 7.889-9.56 ± 8.668
Statistical analysis
  • Placebo vs JNJ-77242113 25 mg QD · Mixed-Effect Model Repeated Measure · p = =0.002 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Mixed-Effect Model Repeated Measure · p = =0.002 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg QD · Mixed-Effect Model Repeated Measure · p = =0.251 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Mixed-Effect Model Repeated Measure · p = =0.087 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Mixed-Effect Model Repeated Measure · p = =0.205 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Mixed-Effect Model Repeated Measure · p = =0.082 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Mixed-Effect Model Repeated Measure · p = =0.010 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg QD · Mixed-Effect Model Repeated Measure · p = =0.357 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Mixed-Effect Model Repeated Measure · p = =0.222 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Mixed-Effect Model Repeated Measure · p = =0.987 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Mixed-Effect Model Repeated Measure · p = =0.390 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Mixed-Effect Model Repeated Measure · p = =0.380 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg QD · Mixed-Effect Model Repeated Measure · p = =0.349 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Mixed-Effect Model Repeated Measure · p = =0.553 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Mixed-Effect Model Repeated Measure · p = =0.318 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Mixed-Effect Model Repeated Measure · p = =0.207 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Mixed-Effect Model Repeated Measure · p = =0.117 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg QD · Mixed-Effect Model Repeated Measure · p = =0.156 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Mixed-Effect Model Repeated Measure · p = =0.019 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Mixed-Effect Model Repeated Measure · p = =0.004 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Mixed-Effect Model Repeated Measure · p = =0.228 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Mixed-Effect Model Repeated Measure · p = =0.034 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg QD · Mixed-Effect Model Repeated Measure · p = =0.197 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Mixed-Effect Model Repeated Measure · p = =0.107 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Mixed-Effect Model Repeated Measure · p = =0.606 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Mixed-Effect Model Repeated Measure · p = =0.004 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Mixed-Effect Model Repeated Measure · p = =0.005 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg QD · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Mixed-Effect Model Repeated Measure · p = =0.005 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Mixed-Effect Model Repeated Measure · p = =0.010 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Mixed-Effect Model Repeated Measure · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
SecondaryPercentage of Participants Who Achieved at Least a 5-point Improvement From Baseline in Each PROMIS-29 Domain at Week 16

PROMIS-29, 29-item generic HRQoL survey, assesses each 7 PROMIS domains (depression; anxiety; physical function; pain interference; fatigue; sleep disturbance; ability to participate in social roles and activities) with 4 questions and pain intensity. Questions ranked on 5-point Likert Scale (1=never, 2=rarely, 3=sometimes, 4=often, 5=always). Pain intensity was rated on 11-point scale (0=no pain; 10=worst imaginable pain). Higher score=worst pain. Each domain includes 4 items, plus a single pain intensity item totaling 29 items. Raw score of each PROMIS domain was converted into a standardized score with mean of 50; SD of 10 (T-Score). Higher PROMIS T-score= more of the concept being measured i.e. higher scores in anxiety, depression, fatigue, pain interference and sleep disturbance) indicated worse symptoms, higher scores in physical function and social roles= better functioning. Baseline: closest measurement taken prior to/at the time of first study drug administration date.

Time frame:
Baseline (Week 0), Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved at Least a 5-point Improvement From Baseline in Each PROMIS-29 Domain at Week 16
Percentage of participantsPlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BID
Physical Function11.623.341.936.637.240.5
Anxiety30.232.644.253.741.954.8
Depression23.327.934.926.832.635.7
Fatigue18.620.923.341.525.642.9
Sleep Disturbance16.323.332.643.923.338.1
Social Roles and Activities23.330.246.556.144.257.1
Pain Interference20.946.555.851.241.964.3
Statistical analysis
  • Placebo vs JNJ-77242113 25 mg QD · Cochran-Mantel-Haenszel · p = =0.160 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Cochran-Mantel-Haenszel · p = =0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Cochran-Mantel-Haenszel · p = =0.008 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Cochran-Mantel-Haenszel · p = =0.006 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Cochran-Mantel-Haenszel · p = =0.003 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg QD · Cochran-Mantel-Haenszel · p = =0.818 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Cochran-Mantel-Haenszel · p = =0.179 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Cochran-Mantel-Haenszel · p = =0.030 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Cochran-Mantel-Haenszel · p = =0.267 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Cochran-Mantel-Haenszel · p = =0.022 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg QD · Cochran-Mantel-Haenszel · p = =0.620 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Cochran-Mantel-Haenszel · p = =0.240 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Cochran-Mantel-Haenszel · p = =0.710 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Cochran-Mantel-Haenszel · p = =0.341 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Cochran-Mantel-Haenszel · p = =0.204 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg QD · Cochran-Mantel-Haenszel · p = =0.786 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Cochran-Mantel-Haenszel · p = =0.597 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Cochran-Mantel-Haenszel · p = =0.023 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Cochran-Mantel-Haenszel · p = =0.438 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Cochran-Mantel-Haenszel · p = =0.017 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg QD · Cochran-Mantel-Haenszel · p = =0.419 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Cochran-Mantel-Haenszel · p = =0.080 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Cochran-Mantel-Haenszel · p = =0.006 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Cochran-Mantel-Haenszel · p = =0.421 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Cochran-Mantel-Haenszel · p = =0.025 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg QD · Cochran-Mantel-Haenszel · p = =0.470 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Cochran-Mantel-Haenszel · p = =0.023 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Cochran-Mantel-Haenszel · p = =0.002 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Cochran-Mantel-Haenszel · p = =0.040 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Cochran-Mantel-Haenszel · p = =0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg QD · Cochran-Mantel-Haenszel · p = =0.013 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 50 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 25 mg BID · Cochran-Mantel-Haenszel · p = =0.004 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg QD · Cochran-Mantel-Haenszel · p = =0.038 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
  • Placebo vs JNJ-77242113 100 mg BID · Cochran-Mantel-Haenszel · p = <0.001 (Dose response assessment was adjusted for multiplicity. Pairwise comparisons between each dose vs placebo were not.)
SecondaryNumber of Participants With Treatment-emergent Adverse Event (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical investigation where participants administered a product or medical device; the event needed not necessarily have a causal relationship with the treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or resulted in congenital anomaly/birth defect. TEAE was defined as any event that occurred at or after the initial administration of study agent.

Time frame:
From Week 0 through Week 20
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Event (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsPlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BID
TEAEs222026201926
TESAEs001020

Adverse events

Collected over From Week 0 through Week 20. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/43 (0%)0/43 (0%)10/43 (23.3%)
JNJ-77242113 25 mg QD0/43 (0%)0/43 (0%)10/43 (23.3%)
JNJ-77242113 50 mg QD0/43 (0%)1/43 (2.3%)15/43 (34.9%)
JNJ-77242113 25 mg BID0/41 (0%)0/41 (0%)12/41 (29.3%)
JNJ-77242113 100 mg QD0/43 (0%)2/43 (4.7%)8/43 (18.6%)
JNJ-77242113 100 mg BID0/42 (0%)0/42 (0%)10/42 (23.8%)
Most frequent serious events
Most frequent serious events
EventPlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BID
Covid-19Infections and infestations0/430/430/430/411/430/42
Infected CystInfections and infestations0/430/431/430/410/430/42
Suicide AttemptPsychiatric disorders0/430/430/430/411/430/42
Most frequent other events
Most frequent other events
EventPlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BID
Covid-19Infections and infestations5/435/433/438/412/434/42
NasopharyngitisInfections and infestations2/431/438/433/411/432/42
DiarrhoeaGastrointestinal disorders1/432/434/432/411/431/42
Upper Respiratory Tract InfectionInfections and infestations1/433/430/430/410/432/42
HeadacheNervous system disorders1/430/431/431/413/431/42
CoughRespiratory, thoracic and mediastinal disorders0/431/431/430/413/431/42

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BIDTotal
Mean43.9 ± 14.744.5 ± 12.7245.1 ± 11.0845.7 ± 11.9144.7 ± 14.1142 ± 11.3444.3 ± 12.65
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BIDTotal
Female18111611111279
Male253227303230176
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BIDTotal
Hispanic or Latino43433219
Not Hispanic or Latino393938374040233
Unknown or Not Reported0111003
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BIDTotal
American Indian or Alaska Native1021105
Asian512977949
Native Hawaiian or Other Pacific Islander0002002
Black or African American0003025
White373031273530190
More than one race0000000
Unknown or Not Reported0111014
Region of Enrollment
Region of Enrollment(Participants)PlaceboJNJ-77242113 25 mg QDJNJ-77242113 50 mg QDJNJ-77242113 25 mg BIDJNJ-77242113 100 mg QDJNJ-77242113 100 mg BIDTotal
Canada76476535
France1121117
Germany88979647
Japan33334420
Korea, South12311311
Poland89119131060
Spain2212119
Taiwan14332013
United Kingdom2000013
United States1087861150
08

Study locations

76 sites
  • Medical Dermatology Specialists
    Phoenix, Arizona 85006, United States
  • Pacific Skin Institute
    Sacramento, California 95815, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Forcare Clinical Research Inc
    Tampa, Florida 33613, United States
  • Atlanta Dermatology, Vein & Research Center
    Alpharetta, Georgia 30022, United States
  • Arlington Dermatology
    Rolling Meadows, Illinois 60008, United States
  • Dawes Fretzin Clinical Research Group LLC
    Indianapolis, Indiana 46250, United States
  • Indiana Clinical Trial Center
    Plainfield, Indiana 46168, United States
  • DermAssociates, PC
    Rockville, Maryland 20850, United States
  • Hamzavi Dermatology
    Fort Gratiot, Michigan 48059, United States
  • Vivida Dermatology
    Las Vegas, Nevada 89119, United States
  • Windsor Dermatology, PC
    East Windsor, New Jersey 08520, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • University of Pittsburgh Department of Dermatology
    Pittsburgh, Pennsylvania 15213, United States
  • Modern Research Associates
    Dallas, Texas 75231, United States
  • Center for Clinical Studies
    Houston, Texas 77004, United States
  • Austin Institute for Clinical Research
    Pflugerville, Texas 78660, United States
  • Center for Clinical Studies
    Webster, Texas 77598, United States
  • Virginia Clinical Research
    Norfolk, Virginia 23502, United States
  • Dermatology Associates
    Seattle, Washington 98101, United States
  • Premier Clinical Research
    Spokane, Washington 99202, United States
  • Dermatrials Research
    Hamilton, Ontario L8N 1Y2, Canada
  • Alliance Clinical Trials
    Waterloo, Ontario N2J 1C4, Canada
  • XLR8 Medical Research
    Windsor, Ontario N8W 1E6, Canada
  • Innovaderm Research
    Montreal, Quebec H2X 2V1, Canada
  • Centre Hospitalier Le Mans
    Le Mans, 72037, France
  • Hopital Charles Nicolle
    Rouen, 76031, France
  • HIA Sainte Anne
    Toulon, 83800, France
  • Fachklinik Bad Bentheim
    Bad Bentheim, 48455, Germany
  • Charite - Universitaetsmedizin Berlin (CCM)
    Berlin, 10117, Germany
  • Rothhaar Studien GmbH
    Berlin, 10783, Germany
  • ISA - Interdisciplinary Study Association GmbH
    Berlin, 10789, Germany
  • Niesmann & Othlinghaus GbR
    Bochum, 44793, Germany
  • Rosenpark Research GmbH
    Darmstadt, 64283, Germany
  • Universitatsklinikum Frankfurt
    Frankfurt am Main, 60590, Germany
  • Derma-Study-Center Friedrichshafen GmbH
    Friedrichshafen, 88045, Germany
  • MensingDerma research GmbH
    Hamburg, 22391, Germany
  • Universitaetsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Universitatsklinikum Schleswig Holstein Kiel
    Kiel, 24105, Germany
  • Universitatsklinikum Leipzig AOR
    Leipzig, 04103, Germany
  • Dermatologische Gemeinschaftspraxis
    Mahlow, 15831, Germany
  • Hautarztpraxis
    Witten, 58453, Germany
  • Yamanashi Prefectural Central Hospital
    Kofu, 400-8506, Japan
  • Miyata Dermatology Clinic
    Matsudo, 271-0092, Japan
  • Takagi Dermatological Clinic
    Obihiro-shi, 080-0013, Japan
  • Kume Clinic
    Sakai, 593 8324, Japan
  • Sapporo Skin Clinic
    Sapporo, 060 0063, Japan
  • Shizuoka General Hospital
    Shizuoka, 420-8527, Japan
  • Shirasaki Dermatology Clinic
    Takaoka, 933-0871, Japan
  • Kumamoto Kenhoku Hospital
    Tamana, 865-0005, Japan
  • Toyama Prefectural Central Hospital
    Toyama, 930 8550, Japan
  • Nomura Dermatology Clinic
    Yokohama, 221 0825, Japan
  • Nzoz Zdrowie Osteo-Medic
    Bialystok, 15-351, Poland
  • Dermed Centrum Medyczne Sp z o o
    Lodz, 90-265, Poland
  • Dermodent Centrum Medyczne Aldona Czajkowska Rafal Czajkowski S C
    Osielsko, 86031, Poland
  • Klinika Ambroziak Estederm Sp. z o.o
    Warsaw, 02-953, Poland
  • Wro Medica
    Wroclaw, 51-685, Poland
  • Pusan National University Hospital
    Busan, 49241, South Korea
  • Seoul National University Bundang Hospital
    Gyeonggi-do, 13620, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Konkuk University Medical Center
    Seoul, 05030, South Korea
  • KyungHee University Hospital
    Seoul, 102-1703, South Korea
  • Hosp. Univ. Germans Trias I Pujol
    Barcelona, 08916, Spain
  • Hosp. Univ. 12 de Octubre
    Madrid, 28041, Spain
  • Hosp. Provincial de Pontevedra
    Pontevedra, 36001, Spain
  • Hosp. Univ. I Politecni La Fe
    Valencia, 46026, Spain
  • Hosp. de Manises
    Valencia, 46940, Spain
  • Chang Gung Memorial Hospital
    Kaohsiung City, 83342, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 70403, Taiwan
  • National Taiwan University Hospital
    Taipei, 10048, Taiwan
  • Chang-Gung Memorial Hospital, LinKou Branch
    Taoyuan, 333, Taiwan
  • Castle Hill Hospital
    Cottingham, HU16 5JQ, United Kingdom
  • Russell's Hall Hospital
    Dudley, DY1 2HQ, United Kingdom
  • Guys and St Thomas NHS Foundation Trust
    London, SE1 9RT, United Kingdom
  • University Hospital Southampton NHS Foundation Trust
    Southampton, SO16 6YD, United Kingdom
  • Mid Yorkshire Hospital NHS Trust- Pinderfields Hospital
    Wakefield, WF1 4DG, United Kingdom
09

References and documents

Publications

  • Strawn D, Krueger JG, Bissonnette R, Eyerich K, Ferris LK, Paller AS, Pinter A, Richards D, Chen EY, Paget K, Horowitz D, Parast R, Rusbuldt JJ, Sendecki J, Bhagat S, Tomsho LP, Chou CH, Polak ME, Keyes BE, Bozenhardt E, Xiong Y, Zhou W, DeKlotz C, Newbold P, Waterworth DM, Miller M, Ota T, Yang YW, Leung MW, Miller LS, Cuff CA, McRae B, Ruane D, Kannan AK. Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis. JCI Insight. 2025 Dec 22;10(24):e193563. doi: 10.1172/jci.insight.193563. eCollection 2025 Dec 22. PubMed 41424381 ↗
  • Bissonnette R, Pinter A, Ferris LK, Gerdes S, Rich P, Vender R, Miller M, Shen YK, Kannan A, Li S, DeKlotz C, Papp K. An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis. N Engl J Med. 2024 Feb 8;390(6):510-521. doi: 10.1056/NEJMoa2308713. PubMed 38324484 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Dec 2022, 10 months.

Results were first posted in Dec 2025, 3 years after primary completion. A results delay was requested in Dec 2023.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 10 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2022
First posted
Feb 4, 2022
StartActual
Feb 3, 2022
Primary completionActual
Dec 15, 2022
CompletionActual
Dec 15, 2022
Results delay requested
Dec 13, 2023
Results first posted
Dec 30, 2025
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05223868
Responsible party
Sponsor
First posted
Feb 4, 2022
Start date
Feb 3, 2022
Primary completion
Dec 15, 2022
Completion
Dec 15, 2022
Results posted
Dec 30, 2025
Last update
Feb 13, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icotrokinra

Start the discussion